Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
Xian-Wu Luo,1 Xue-Qing Du,2 Jie-Li Li,2 Xiao-Ping Liu,3,4 Xiang-Yu Meng3,4 1Department of Health Management, School of Health Sciences, Wuhan University, 2Department of Hematology, Zhongnan Hospital of Wuhan University, 3Department of Evidence-Based Medicine and Clinical Epidemiology, Second Clinica...
Main Authors: | Luo XW, Du XQ, Li JL, Liu XP, Meng XY |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-08-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/treatment-options-for-refractoryrelapsed-multiple-myeloma-an-updated-e-peer-reviewed-article-CMAR |
Similar Items
-
How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01) -
Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01) -
Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01) -
Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan
by: Chieh-Lin Jerry Teng, et al.
Published: (2024-12-01) -
Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01)